The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1

Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) approved for the treatment of HER2 (human epidermal growth factor receptor 2)-positive breast cancer. T-DM1 consists of trastuzumab covalently linked to the cytotoxic maytansinoid DM1 via a non-cleavable linker. Despite its efficacy,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Nadal-Serrano, Mercedes, Morancho, Beatriz, Escrivá-de-Romaní, Santiago, Bernadó Morales, Cristina, Luque, Antonio, Escorihuela, Marta, Espinosa Bravo, Martín, Peg, Vicente, Dijcks, Fred A., Dokter, Wim H.A., Cortés, Javier, Saura, Cristina, Arribas, Joaquín
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7139846/
https://ncbi.nlm.nih.gov/pubmed/32183023
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12030670
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars